Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0732 183X "

Sökning: L773:0732 183X

Sortera/gruppera träfflistan
  • He, Wei, et al. (författare)
  • Predictors for discontinuation of adjuvant hormone therapy in breast cancer patients
  • 2015
  • Ingår i: Journal of clinical oncology. - Stockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics. - 0732-183X.
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: To identify predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. PATIENTS AND METHODS: We conducted a record-linkage study based on data from Stockholm-Gotland Breast Cancer Register, Swedish Prescribed Drug Register, and self-reported questionnaire. Women diagnosed with breast cancer between 2005 and 2008 in Stockholm, Sweden, were prospectively followed for 5 years until 2013, starting from their first prescription of tamoxifen or aromatase inhibitors (N = 3,395). RESULTS: Family history of ovarian cancer (hazard ratio [HR], 1.55; 95% CI, 1.19 to 2.02); younger (< 40 years; HR, 1.39; 95% CI, 1.08 to 1.78) and older (>/= 65 years; HR, 1.15; 95% CI, 1.03 to 1.28) age; higher Charlson comorbidity index (>/= 2 v 0; HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI drugs (HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1.49) were identified as baseline predictors for hormonal treatment discontinuation. Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), antidepressants (HR, 1.22; 95% CI, 1.06 to 1.40), or GI drugs (HR, 1.27; 95% CI, 1.13 to 1.43), and switching therapy between tamoxifen and aromatase inhibitors (HR, 1.50; 95% CI, 1.23 to 1.83) during the first year of hormonal treatment were associated with increased risk of discontinuation during the next 4 years. CONCLUSION: Predictors identified in our study can be used in developing targeted intervention to prevent adjuvant hormone therapy discontinuation and subsequently to improve breast cancer outcomes.
  • Holm, Johanna, et al. (författare)
  • Associations of breast cancer risk prediction tools with tumor characteristics and metastasis
  • 2016
  • Ingår i: Journal of Clinical Oncology. - Stockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics. - 0732-183X. ; 34:3, s. 251-U109
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: The association between established risk factors for breast cancer and subtypes or prognosis of the disease is not well known. We analyzed whether the Tyrer-Cuzick–predicted 10-year breast cancer risk score (TCRS), mammographic density (MD), and a 77-single nucleotide polymorphism polygenic risk score (PRS) were associated with breast cancer tumor prognosticators and risk of distant metastasis. Patients and Methods: We used a case-only design in a population-based cohort of 5,500 Swedish patients with breast cancer. Logistic and multinomial logistic regression of outcomes, estrogen receptor (ER) status, lymph node involvement, tumor size, and grade was performed with TCRS, PRS, and percent MD as exposures. Cox proportional hazard models were used to estimate hazard ratios (HRs) of distant metastasis. Results: Women at high risk for breast cancer based on PRS and/or TCRS were significantly more likely to be diagnosed with favorable prognosticators, such as ER-positive and low-grade tumors. In contrast, PRS weighted on ER-negative disease was associated with ER-negative tumors. When stratifying by age, the associations of TCRS with favorable prognosticators were restricted to women younger than age 50. Women scoring high in both TCRS and PRS had a lower risk of distant metastasis (HR, 0.69; 95% CI, 0.49 to 0.98). MD was not associated with any of the examined prognosticators. Conclusion: Women at high risk for breast cancer based on genetic and lifestyle factors were significantly more likely to be diagnosed with breast cancers with a favorable prognosis. Better knowledge of subtype- specific risk factors could be vital for the success of prevention programs aimed at lowering mortality.
  • Holm, Johanna, et al. (författare)
  • Risk factors and tumor characteristics of interval cancers by mammographic density
  • 2015
  • Ingår i: Journal of Clinical Oncology. - Stockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics. - 0732-183X. ; 33:9, s. 1030-
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: To compare tumor characteristics and risk factors of interval breast cancers and screen-detected breast cancers, taking mammographic density into account. Patients and Methods: Women diagnosed with invasive breast cancer from 2001 to 2008 in Stockholm, Sweden, with data on tumor characteristics (n ? 4,091), risk factors, and mammographic density (n ? 1,957) were included. Logistic regression was used to compare interval breast cancers with screen- detected breast cancers, overall and by highest and lowest quartiles of percent mammo- graphic density. Results: Compared with screen-detected breast cancers, interval breast cancers in nondense breasts (? 20% mammographic density) were significantly more likely to exhibit lymph node involvement (odds ratio [OR], 3.55; 95% CI, 1.74 to 7.13) and to be estrogen receptor negative (OR, 4.05; 95% CI, 2.24 to 7.25), human epidermal growth factor receptor 2 positive (OR, 5.17; 95% CI, 1.64 to 17.01), progesterone receptor negative (OR, 2.63; 95% CI, 1.58 to 4.38), and triple negative (OR, 5.33; 95% CI, 1.21 to 22.46). In contrast, interval breast cancers in dense breasts (? 40.9% mammographic density) were less aggressive than interval breast cancers in nondense breasts (overall difference, P ? .008) and were phenotypically more similar to screen-detected breast cancers. Risk factors differentially associated with interval breast cancer relative to screen- detected breast cancer after adjusting for age and mammographic density were family history of breast cancer (OR, 1.32; 95% CI, 1.02 to 1.70), current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38 to 2.44), and body mass index more than 25 kg/m2 (OR, 0.49; 95% CI, 0.29 to 0.82). Conclusion: Interval breast cancers in women with low mammographic density have the most aggressive phenotype. The effect of HRT on interval breast cancer risk is not fully explained by mammographic density. Family history is associated with interval breast cancers, possibly indicating disparate genetic background of screen-detected breast cancers and interval breast cancers.
  • Abrahamsson, Jonas, 1954, et al. (författare)
  • Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.
  • 2011
  • Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - : American Society of Clinical Oncology. - 1527-7755 .- 0732-183X. ; 29:3, s. 310-5
  • Tidskriftsartikel (refereegranskat)abstract
    • To evaluate the early treatment response in children with acute myeloid leukemia (AML) using a response-guided induction strategy that includes idarubicin in the first course.
  • Agudo, Antonio, et al. (författare)
  • Impact of Cigarette Smoking on Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study
  • 2012
  • Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 30:36, s. 4550-4557
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose Our aim was to assess the impact of cigarette smoking on the risk of the tumors classified by the International Agency for Research on Cancer as causally associated with smoking, referred to as tobacco-related cancers (TRC). Methods The study population included 441,211 participants (133,018 men and 308,193 women) from the European Prospective Investigation Into Cancer and Nutrition. We investigated 14,563 participants who developed a TRC during an average follow-up of 11 years. The impact of smoking cigarettes on cancer risk was assessed by the population attributable fraction (AF(p)), calculated using the adjusted hazard ratios and 95% CI for current and former smokers, plus either the prevalence of smoking among cancer cases or estimates from surveys in representative samples of the population in each country. Results The proportion of all TRC attributable to cigarette smoking was 34.9% (95% CI, 32.5 to 37.4) using the smoking prevalence among cases and 36.2% (95% CI, 33.7 to 38.6) using the smoking prevalence from the population. The AF(p) were above 80% for cancers of the lung and larynx, between 20% and 50% for most respiratory and digestive cancers and tumors from the lower urinary tract, and below 20% for the remaining TRC. Conclusion Using data on cancer incidence for 2008 and our AF(p) estimates, about 270,000 new cancer diagnoses per year can be considered attributable to cigarette smoking in the eight European countries with available data for both men and women (Italy, Spain, United Kingdom, the Netherlands, Greece, Germany, Sweden, Denmark). 
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (304)
konferensbidrag (302)
forskningsöversikt (5)
annan publikation (1)
Typ av innehåll
övrigt vetenskapligt (370)
refereegranskat (242)
Glimelius, Bengt (31)
Glimelius, B (22)
Bergh, J (21)
Hansson, J. (19)
Bergh, JCS (18)
Jonsson, B (15)
visa fler...
Mellstedt, H (14)
Nahi, H (12)
Ringden, O (11)
Avall-Lundqvist, E (11)
Osterborg, A (10)
Johansson, H (10)
Holmberg, Lars (10)
Stattin, Pär (9)
LAMBE, M (9)
Fornander, T (9)
Masucci, GV (9)
Lind, PA (9)
Brandberg, Y (9)
Usmani, SZ (9)
Wilking, N (9)
Hatschek, T (8)
Eklund, M (8)
Garmo, Hans (8)
Gronberg, H (8)
Hellstrom, M (8)
Sandstrom, P. (7)
Wilking, U (7)
Laurell, Anna (7)
Plesner, T (7)
Greil, R (7)
Cohn-Cedermark, G (7)
Lindman, Henrik (7)
Harmenberg, U. (7)
Dahl, O. (7)
Yachnin, J (7)
Mateos, MV (7)
Gnant, M. (6)
Pukkala, E (6)
Kaaks, Rudolf (6)
Moreau, P (6)
Hall, P (6)
Nilsson, S. (6)
Nilsson, B (6)
Akre, O (6)
Sorbye, H. (6)
Nordstrom, T (6)
Stahl, O (6)
Cunningham, David (6)
Pfeiffer, P (6)
visa färre...
Karolinska Institutet (420)
Uppsala universitet (131)
Lunds universitet (56)
Umeå universitet (49)
Göteborgs universitet (29)
Linköpings universitet (22)
visa fler...
Örebro universitet (14)
Kungliga Tekniska Högskolan (8)
Marie Cederschiöld högskola (5)
Högskolan Kristianstad (1)
Stockholms universitet (1)
Malmö universitet (1)
Linnéuniversitetet (1)
Högskolan Dalarna (1)
visa färre...
Engelska (612)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (203)
Naturvetenskap (2)
Samhällsvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy